Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Hagberg

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
European Journal of Clinical Pharmacology|December 8, 2009
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patientsFilip Josephson, Maria C H Andersson, Leo Flamholc, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 22, 2016
Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIVBirgitta Anesten, Aylin Yilmaz, Lars Hagberg, et al.
Ebiomedicine|June 21, 2016
Corrigendum to: "Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study" [EBioMedicine 3 (216) 135-140]Magnus Gisslén, Richard W Price, Ulf Andreasson, et al.
Expert Review of Molecular Diagnostics|June 10, 2017
Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controlsAylin Yilmaz, Kaj Blennow, Lars Hagberg, et al.
Ebiomedicine|February 13, 2016
Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional StudyMagnus Gisslén, Richard W Price, Ulf Andreasson, et al.
Neurology|October 2, 2020
CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case SeriesArvid Edén, Nelly Kanberg, Johanna Gostner, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 21, 2018
CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infectionMagnus Gisslén, Amanda Heslegrave, Elena Veleva, et al.
Plos One|December 27, 2014
Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detectionJulia Peterson, Magnus Gisslen, Henrik Zetterberg, et al.
AIDS Research and Human Retroviruses|December 17, 2009
Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolatesUlf Karlsson, Liselotte Antonsson, Johanna Repits, et al.
Journal of Neuroimmunology|December 8, 2004
Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system diseaseNicolai Sidenius, Manuela Nebuloni, Stefania Sala, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
European Journal of Clinical Pharmacology|December 8, 2009
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patientsFilip Josephson, Maria C H Andersson, Leo Flamholc, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 22, 2016
Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIVBirgitta Anesten, Aylin Yilmaz, Lars Hagberg, et al.
Ebiomedicine|June 21, 2016
Corrigendum to: "Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study" [EBioMedicine 3 (216) 135-140]Magnus Gisslén, Richard W Price, Ulf Andreasson, et al.
Expert Review of Molecular Diagnostics|June 10, 2017
Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controlsAylin Yilmaz, Kaj Blennow, Lars Hagberg, et al.
Ebiomedicine|February 13, 2016
Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional StudyMagnus Gisslén, Richard W Price, Ulf Andreasson, et al.
Neurology|October 2, 2020
CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case SeriesArvid Edén, Nelly Kanberg, Johanna Gostner, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 21, 2018
CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infectionMagnus Gisslén, Amanda Heslegrave, Elena Veleva, et al.
Plos One|December 27, 2014
Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detectionJulia Peterson, Magnus Gisslen, Henrik Zetterberg, et al.
AIDS Research and Human Retroviruses|December 17, 2009
Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolatesUlf Karlsson, Liselotte Antonsson, Johanna Repits, et al.
Journal of Neuroimmunology|December 8, 2004
Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system diseaseNicolai Sidenius, Manuela Nebuloni, Stefania Sala, et al.
Pageof 14